

#121

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Wednesday, January 05, 2022 12:44:37 PM
Last Modified: Wednesday, January 05, 2022 12:49:44 PM
Time Spent: 00:05:06
IP Address: 72.11.187.221

Page 1: Disclosure of conflict of interest information

Q1

Process:1. Complete the conflict of interest disclosure form and submit to the CPD provider organization or scientific planning committee, as directed.2. Disclosures must be made to the audience whether you do or do not have a relationship to disclose.3. Speakers must disclose conflicts verbally and in writing on a slide at the beginning of a presentation. All other individual's conflicts must be disclosed either in writing on a slide at the beginning of a presentation or be included in the written conference materials.4. Those responsible for developing or delivering content must ensure that the content and/or materials presented provide (where applicable) a balanced view across all relevant options related to the content area.5. The description of therapeutic options must utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

By clicking "NEXT," you confirm that you have read and agree with the above requirements.

Page 2: Disclosure of conflict of interest form

Q2

Name

Dr Éric Paradis

Q3

Today's Date

Date

01/05/2022

Q4

What is your role in this year's CanSAGE CPD activity?
Select all that apply.

Speaker / Presenter

Q5

Yes

Do you have a relationship with a for-profit and/or a not-for-profit organization to disclose?

Q6

Please indicate the for-profit or not-for-profit organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship. Answer format: NAME (description), NAME (description)

Any direct financial payments including receipt of honoraria

Présentateur :AbbVie , MedTronic , ConMed ;

Funded grants or clinical trials

Projets de recherches : Capture , GRACE (AbbVie)

Q7

No

For speakers only: I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).

Q8

Yes

For speakers only: I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names), and not reflect exclusivity and branding.

Q9

I agree

By clicking "I agree" you are acknowledging that the above information is accurate and that you understand that this information will be publicly available.
